Teladoc CEO Charles Divita III Converts Awards, Sells 18,327 Shares

What Happened
Charles Divita III, CEO of Teladoc Health (TDOC), had restricted and performance stock units convert into common shares on Sept. 1, 2026 (two conversions of 42,277 and 1,966 shares). Following the conversions, he sold 18,327 shares in the open market on Sept. 2, 2026 at $6.30 per share, for proceeds of $115,478. The conversion/derivative entries appear as “M” (exercise/conversion of derivative) on the Form 4; the filing’s footnotes state the sale was to cover tax withholding obligations related to the vesting.

Key Details

• Transaction dates/prices:
  • 2026-09-01: Conversion/exercise of derivative (M) — 42,277 shares and 1,966 shares converted to common stock (reported at $0.00 for derivative disposition entries).
  • 2026-09-02: Open-market sale — 18,327 shares at $6.30 each, proceeds $115,478.
• Shares owned after transaction: Not specified in the provided filing extract.
• Notable footnotes from the filing:
  • F1/F2: RSUs and PSUs convert one-for-one into TDOC common stock.
  • F3: The shares sold were to cover tax withholding on the vesting of PSUs/RSUs.
  • F4/F5: Background on grants — e.g., a 507,322 RSU grant on 3/1/2025 and 23,591 PSUs earned on 3/1/2026 with multi-step vesting schedules.
• Filing/Timeliness: Report filed 2026-09-03 for transactions dated Sept. 1–2, 2026 (filing does not appear late based on provided dates).

Context
The “M” code and footnotes indicate these were conversions of company awards (RSUs/PSUs) into shares rather than purchases of stock. The subsequent sale of 18,327 shares was used to satisfy tax-withholding obligations tied to the vesting — a common, routine insider transaction that typically reflects administrative needs rather than a market signal.